The global head of neurology development at Sanofi discussed the safety profile of tolebrutinib, an investigational BTK inhibitor, and how treatments like it may help transform the care for patients with multiple sclerosis. [WATCH TIME: 5 minutes]
Erik Wallstroem, MD, PhD
Advertisement
Articles by Erik Wallstroem, MD, PhD
The global head of neurology development at Sanofi provided insight on how tolebrutinib may overcome the challenges of treating non-relapsing secondary progressive multiple sclerosis. [WATCH TIME: 5 minutes]
Advertisement
Latest Updated Articles
Therapeutic Potential of BTK Inhibitor Tolebrutinib in Non-Relapsing Secondary Progressive Multiple Sclerosis: Erik Wallstroem, MD, PhDPublished: September 6th 2024 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
NRLP3 Inhibitor VTX3232 Well-Tolerated, Improves Parkinson Symptoms in Phase 2a Trial
2
Exploring the Role of Aerobic Exercise in Promoting Remyelination in Multiple Sclerosis: Lindsey Wooliscroft, MD, MS
3
Rethinking Progressive MS Studies to Better Include Advanced Patients: Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath
4
Targeting CD19+ B Cells With Inebilizumab in Myasthenia Gravis
5
